Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

STT's $22.8m convertible bridge facility

11 Jan 2018 07:00

RNS Number : 5468B
Allied Minds PLC
11 January 2018
 

Update on Spin Transfer Technologies' $22.8 million convertible bridge facility

 

 

Boston MA - 11 January 2018 - Allied Minds (ALM: LSE) today announces that it has syndicated $10.28 million of the $22.8 million convertible bridge facility commitment it put in place for Spin Transfer Technologies (STT) in October 2017.

 

Existing STT shareholders Invesco Asset Management (Invesco) and Woodford Investment Management (WIM) will subscribe $10.28 million for convertible equity securities in STT, and Allied Minds commitment to the convertible bridge facility will be reduced by a corresponding amount to $12.52 million.

 

The facility is designed to bridge STT to the completion of a planned Series B funding round targeting strategic investors.

 

 

ENDS

 

For more information, please contact:

 

Allied Minds plc

Neil Pizey, Head of Corporate Development

+44 7771 872 922

FTI Consulting

Ben Atwell / Brett Pollard

+44 20 3727 1000

 

 

About Allied Minds

Based in Boston, Allied Minds plc is an IP commercialisation company focused on technology and life sciences. With extensive access to U.S. federal government laboratories and universities, as well as partnerships with leading U.S. corporations, Allied Minds forms, funds, and operates a portfolio of companies with the objective of delivering successful liquidity events that will generate attractive long-term returns for its investors and stakeholders. Allied Minds supports its businesses with capital, resources, and expertise.

For more information, please visit www.alliedminds.com

 

About STT

Spin Transfer Technologies, Inc. (STT) is seeking to develop ST-MRAM technologies that uniquely combine patented magnetics technologies, circuits and memory architectures to create the industry's lowest-cost, highest-performance ST-MRAM memories. STT's disruptive ST-MRAM solutions are ideal replacements for embedded and stand-alone SRAMs as well as future DRAM devices, affecting more than half of the $300+ billion semiconductor industry. The company was established by Allied Minds and New York University. For more information, please visit www.spintransfer.com.

 

Further information on the fund-raise

Of the $10.28 million STT convertible equity securities subscribed, Invesco contributed $6.0 million for the purchase of 600 securities and WIM contributed $4.28 million for the purchase of 428 securities Both Invesco and WIM are substantial shareholders of Allied Minds pursuant to the Listing Rules and thus, this transaction is a smaller related party transaction falling within the scope of Listing Rule 11.1.10R.

 

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to Allied Minds' future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in Allied Minds' regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of Allied Minds and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure Guidance and Transparency Rules, neither Allied Minds nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKKDKFBKDBDD
Date   Source Headline
31st Jan 20173:55 pmRNSTotal Voting Rights
30th Jan 201712:02 pmRNSPrice Monitoring Extension
3rd Jan 20172:48 pmRNSHolding(s) in Company
3rd Jan 20172:11 pmRNSTotal Voting Rights
13th Dec 20167:00 amRNSFormation of Signature Medical, Inc.
9th Dec 20165:04 pmRNSHolding(s) in Company
7th Dec 20164:34 pmRNSHolding(s) in Company
6th Dec 20165:05 pmRNSHolding(s) in Company
6th Dec 20165:04 pmRNSHolding(s) in Company
2nd Dec 20167:00 amRNSResults of equity placing
1st Dec 20164:50 pmRNSProposed Equity Placing
23rd Nov 20167:00 amRNSHawkEye 360 Raises $11m in Series A Financing
21st Nov 20167:00 amRNSFormation of Vatic Materials, Inc.
18th Nov 20163:15 pmRNSBlock Listing Six Monthly Return
11th Nov 20165:17 pmRNSHolding(s) in Company
24th Oct 20167:00 amRNSPrecision Biopsy Raises $5.0 Million
17th Oct 201612:07 pmRNSSecond Price Monitoring Extn
17th Oct 201612:02 pmRNSPrice Monitoring Extension
29th Sep 20167:00 amRNSAllied Minds & GE Ventures Form Strategic Alliance
8th Sep 201612:02 pmRNSPrice Monitoring Extension
31st Aug 20165:11 pmRNSTotal Voting Rights
25th Aug 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSAllied Minds Secures $20m Debt Facility from SVB
22nd Aug 20167:00 amRNSAllied Minds' Subsidiary ABLS II Raises $15m
1st Aug 20167:00 amRNSSciFluor Enters Clinical Trial Stage
29th Jul 201610:30 amRNSTotal Voting Rights
13th Jul 201610:02 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:00 amRNSDirector/PDMR Shareholding
7th Jul 20167:00 amRNSLong Term Incentive Plan - Listing Application
30th Jun 20167:00 amRNSTotal Voting Rights
22nd Jun 20164:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20164:35 pmRNSPrice Monitoring Extension
14th Jun 20162:38 pmRNSDirector/PDMR Shareholding
13th Jun 20165:18 pmRNSDirector/PDMR Shareholding
31st May 20164:44 pmRNSBlocklisting Six Monthly Return
26th May 20165:23 pmRNSResult of AGM
26th May 20167:00 amRNSAGM Statement
25th May 20167:00 amRNSABLS II Completes Drug Feasibility Programme
13th May 20167:00 amRNSDirector/PDMR Shareholding
10th May 20164:30 pmRNSLong Term Incentive Plan
28th Apr 201612:33 pmRNSHolding(s) in Company
26th Apr 20167:00 amRNSAllied Minds Raises $80m for ABLS Capital
25th Apr 20167:00 amRNSAnnual Financial Report
19th Apr 20167:00 amRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSABLS agrees license with NYU
10th Feb 20164:40 pmRNSSecond Price Monitoring Extn
10th Feb 20164:36 pmRNSPrice Monitoring Extension
9th Feb 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.